Breaking Finance News

A report released today by Oddo Seydler Bank AG about STRATEC Biomedical (ETR:SBS) bumps the target price to 56.00EUR

In a statement issued on Friday September 30, 2016 Oddo Seydler Bank AG raised the target of STRATEC Biomedical (ETR:SBS) to 56.00EUR indicating a potential upside of 0.10%.

On 09/23/2016, Joh. Berenberg Gossler & Co. KG released a statement on STRATEC Biomedical (ETR:SBS) upped the target price from 0.00EUR to 53.00EUR that suggested an upside of 0.01%.

Showing a price of 50.76EUR, STRATEC Biomedical (ETR:SBS) traded -1.07% lower on the day. With the last stock price close up 13.49% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. SBS has recorded a 50-day moving average of 9.16EUR and a 200-day average of 8.16EUR. Trading volume was down over the average, with 1,522,310 shares of SBS changing hands under the typical 2,024,700

Performance Chart

STRATEC Biomedical (ETR:SBS)

With a total market value of 0 EUR, STRATEC Biomedical has PE ratio of 15.59 with a one year low of 3.98EUR and a one year high of 9.83EUR .

A total of 3 firms have issued a report on the stock. zero equity analysts rating the company a strong buy, zero brokerages rating the company a buy, zero analysts rating the stock a hold, 0 brokers rating the company a underperform, and finally zero firms rating the stock a sell with a consensus target price of 28.48EUR.

About STRATEC Biomedical (ETR:SBS)

STRATEC Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. STRATEC Group operats through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.